The latest update is out from Fresh Tracks Therapeutics (FRTX).
Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. mutually agreed to terminate their license agreement from February 2022, which granted Fresh Tracks exclusive rights to develop and market Carna’s novel STING inhibitors. While the deal initially involved a $2 million payment and potential additional payments of up to $258 million based on milestones, plus royalties on sales, these obligations have now ceased under the termination agreement, although terms regarding indemnification and confidentiality remain effective.
See more insights into FRTX stock on TipRanks’ Stock Analysis page.
